Aubagio Reduces Lesions in Children in Trial, but Relapse Data Troubled
Aubagio (teriflunomide) failed to significantly reduce relapses in children with multiple sclerosis (MS), but two years of treatment…
Articles by Steve Bryson, PhD
Vitamin D Deficiency Linked to Early Cognitive Difficulties in Study
Low vitamin D levels in the bloodstream are associated with slower information processing speeds in people with early-stage multiple sclerosis…
Robotic Devices Help Improve Walking for Those with Severe Deficits
Using robotic devices during gait training can improve walking abilities in people with multiple sclerosis (MS), particularly among those…
Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People
A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated…
Coated Vesicles Found to Safely Reduce Disease Progression in Mice
Extracellular vesicles or EVs — tiny sacs of material excreted by cells — that have been coated with protein receptors…
Mindfulness Helped MS Patients Cope With Symptoms
Mindfulness-based interventions (MBIs) helped people with multiple sclerosis (MS) cope with symptoms, and many said they would recommend these…
1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML
One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare brain infection — called progressive…
JC Virus Mutations May Predict Rare Brain Infection Linked to Tysabri
Mutations in the John Cunningham virus may serve as an early predictor for a rare brain infection in multiple…
Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational…
#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination
An investigational immunotherapy, ATA188Â showed it could reverse disability and improve exercise capacity in people with progressive forms of…
Depression Greatly Raises Patients’ Risk of Vascular Disease, Death
Depression in multiple sclerosis (MS) patients greatly raises their risk of vascular disease and death by any cause, a study…
ADS-5102 Aided Walking Speed in Select MS Patients in INROADS Trial
An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in…
Combo of Biomarkers Predict Future Disease Activity
In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in…
Interferon Beta-1b Effective, Safe for Older MS Patients: Real-world Study
A real-world study confirmed the effectiveness and safety of interferon beta-1b in treating older adults with multiple sclerosis (MS),…
COVID-19 Vaccine Trial Testing Extra Dose in MS, Other Diseases
A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose…
Sonoma Raises $265M to Advance Its T-cell Therapies
Sonoma Biotherapeutics has raised $265 million in investment funding to support the development and production of novel immune T-cell…
CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial
Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis…
MD1003 Aids Walking Speed in Progressive MS, But Carries Risks
High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on…
Canadian Patients Say Their Top Concern Is Access to MS Providers
Accessing healthcare providers knowledgeable about multiple sclerosis (MS) and being able to afford additional services to improve overall health…
Swank and Wahls Diets Found to Help with MS Fatigue, Quality of Life
The low-fat Swank diet and the Wahls elimination diet reduced fatigue and improved quality of life after three months for…
Tysabri Safe and Effective Taken Every 6 Weeks, NOVA Trial Finds
Tysabri (natalizumab) given every six weeks was as safe and effective over nearly 1.5 years of use as its…
Combinations of Variants Contribute to Genetic MS Risk
Genetic susceptibility to multiple sclerosis (MS) depends on an individual’s particular combination of multiple risk variants, a study reveals.
Sugar Molecules in Yeast Cells Prevent Inflammation in Mouse Model
A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis…
Anti-inflammatory Molecule Can Pass Brain Barrier, May Treat MS
A potential anti-inflammatory treatment, xB3-IL-1RA was able to reach the central nervous system of a rodent model of multiple…
Cambridge-1 ‘Supercomputer’ to Advance UK Research in Ills Like MS
Nvidia announced the launch of the U.K.’s most powerful supercomputer — called Cambridge-1 — which uses a combination of…
High-Potency SPMS Meds Limit Relapses, Study Finds
High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis…
Early High-efficacy Therapies May Be Better to Eliminate MS Activity
Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no…
Scientists Discover Enzyme Needed for Activating Myelin Repair
The enzyme TET1, which is progressively lost with age, is essential to activate genes needed to repair myelin…
University Alumni Donate $7.5M to Support Research Into MS, Like Diseases
John and Catherine Seibyl, both alumni of Case Western Reserve University (CWRU) in Ohio, have pledged $7.5 million to the…
Gilenya’s Optimal Dose for RRMS Confirmed in Review of Clinical Trials
Gilenya (fingolimod) at its approved 0.5 mg daily dose continues to be the optimal dose for people with relapsing-remitting MS…